Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
暂无分享,去创建一个
Tomoko Tadokoro | A. Morishita | S. Fujihara | H. Iwama | Koji Fujita | K. Oura | J. Tani | T. Himoto | H. Kobara | Mai Nakahara | Kei Takuma | Tsutomu Masaki
[1] Liu Yang,et al. miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma. , 2019, Biochemical and biophysical research communications.
[2] J. Akiba,et al. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo , 2019, AntiCancer Research.
[3] Huajun Zhao,et al. HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape , 2019, Cells.
[4] Fei Wang,et al. miR-491-5p functions as a tumor suppressor by targeting IGF2 in colorectal cancer , 2019, Cancer management and research.
[5] Fugen Li,et al. Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepatocellular carcinoma patient-derived cell models , 2018, Oncology reports.
[6] Hang-Seok Chang,et al. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer , 2018, BMC Cancer.
[7] Yuji Yamamoto,et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models , 2018, Cancer medicine.
[8] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[9] Alan D. Lopez,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.
[10] Chao Zeng,et al. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop. , 2017, Cancer letters.
[11] Guihua Wang,et al. Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. , 2017, Oncology reports.
[12] Chen Huang,et al. miR-491-5p, mediated by Foxi1, functions as a tumor suppressor by targeting Wnt3a/β-catenin signaling in the development of gastric cancer , 2017, Cell Death and Disease.
[13] Tomoyuki Suzuki,et al. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma , 2016, Molecular Cancer Therapeutics.
[14] Tsutomu Masaki,et al. MicroRNA profiles in various hepatocellular carcinoma cell lines , 2016, Oncology letters.
[15] J. Lund,et al. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma , 2016, The oncologist.
[16] J. Larkin,et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.
[17] F. Lv,et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation , 2015, Oncotarget.
[18] T. Masaki,et al. MicroRNA profiles in cisplatin-induced apoptosis of hepatocellular carcinoma cells. , 2015, International journal of oncology.
[19] Masao Iwata,et al. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.
[20] Raquel Urtasun,et al. Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System , 2012, PloS one.
[21] Xianghuo He,et al. Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy , 2011, Acta Pharmacologica Sinica.
[22] Y. Sekido,et al. E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles , 2009, Clinical Cancer Research.
[23] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[24] Y. Funahashi,et al. Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase , 2008, Clinical Cancer Research.
[25] Kuen-Feng Chen,et al. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. , 2008, Cancer research.
[26] Yuji Yamamoto,et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.
[27] H. El‐Serag,et al. Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.
[28] P. Hou,et al. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. , 2017, American journal of cancer research.
[29] Kuen-Feng Chen,et al. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. , 2010, Journal of hepatology.